September 8, 2026- Teleflex Incorporated announced the appointment of Sean M. Salmon to its Board of Directors, effective September 8, 2026. Mr. Salmon brings over three decades of global leadership experience in the medical device and pharmaceutical industries, culminating in more than 20 years at Medtronic plc.
He most recently served as Executive Vice President and President of its Cardiovascular Portfolio, a global business with fiscal 2025 revenue of approximately $12.5 billion for which Mr. Salmon was instrumental in developing the growth strategy. He previously held leadership roles across Medtronic’s Diabetes, Coronary and Structural Heart, and Coronary and Renal Denervation businesses. Mr. Salmon currently serves as an independent director of Adagio Medical Holdings, Inc.
The Teleflex Board is now comprised of nine directors, eight of whom are independent. Mr. Salmon will also serve on the Growth and Operating Committee. The committee was established earlier this year to support management’s continued execution of Teleflex’s strategic transformation, including ongoing initiatives to strengthen operational execution, identify growth opportunities and enhance accountability across the organization.